A Phase IIA, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU)
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs GDC 0853 (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Sponsors Roche
- 23 May 2017 Planned End Date changed from 10 Mar 2018 to 10 Apr 2018.
- 23 May 2017 Planned primary completion date changed from 10 Mar 2018 to 10 Apr 2018.
- 23 May 2017 Status changed from not yet recruiting to recruiting.